

# PEREGRINE PHARMACEUTICALS INC

## FORM S-8

(Securities Registration: Employee Benefit Plan)

Filed 12/12/16

Address	14282 FRANKLIN AVE TUSTIN, CA 92780
Telephone	7145086000
CIK	0000704562
Symbol	PPHM
SIC Code	2834 - Pharmaceutical Preparations
Industry	Pharmaceuticals
Sector	Healthcare
Fiscal Year	04/30

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

**PEREGRINE PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

**95-3698422**

(State or other jurisdiction of  
of incorporation or organization)

(IRS Employer  
Identification No.)

**14282 Franklin Avenue  
Tustin, California**

**92780-7017**

(Address of principal executive offices)

(Zip Code)

**2010 Employee Stock Purchase Plan**  
(Full title of the plan)

**Mark R. Ziebell  
Vice President and General Counsel  
14282 Franklin Avenue  
Tustin, California 92780-7017  
(714) 508-6000**

(Name, address and telephone number, including area code, of agent for service)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act (check one):

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

(Do not check if a smaller  
reporting company)

**CALCULATION OF REGISTRATION FEE**

Title of Securities to be Registered	Amount to be Registered (1)	Proposed Maximum Offering Price Per Share (2)	Proposed Maximum Aggregate Offering Price	Amount of Registration Fee
Common Stock, \$0.001 par value	10,000,000 shares	\$ 0.26435	\$ 2,643,500	\$ 306.38
<b>TOTAL</b>	10,000,000 shares		\$ 2,643,500	\$ 306.38

(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of common stock that may become issuable under the 2010 Employee Stock Purchase Plan, as amended (the "ESPP"), by reason of any stock dividend, stock split, recapitalization or similar adjustments.

(2) Estimated solely for purposes of calculating the registration fee pursuant to Rules 457(c) and 457(h) under the Securities Act based upon 85% of the average of the high and low prices of the Registrant's common stock as reported on the NASDAQ Capital Market on December 7, 2016. Pursuant to the ESPP, which is incorporated by reference herein, the purchase price per share at which shares of common stock are sold in an offering period will be equal to 85% of the lower of the fair market value of the common stock on the first trading day of the offering period or on the last trading day of the offering period.

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 is filed by the Registrant to register an additional 10,000,000 shares of common stock, par value \$0.001 per share, of Peregrine Pharmaceuticals, Inc., (the "Company") reserved and available for issuance under the 2010 Employee Stock Purchase Plan, as amended, pursuant to an amendment of such plan authorized by the stockholders of the Registrant on October 13, 2016. Pursuant to General Instruction E of Form S-8, the contents of the Registration Statement on Form S-8 previously filed with the Securities and Exchange Commission (the "SEC") on December 9, 2010 (File No. 333-171067) are incorporated herein by reference and made a part hereof.

## PART II

### INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

#### Item 3. Incorporation of Certain Documents by Reference.

The following documents filed by the Company with the SEC are incorporated by reference into this Registration Statement and are deemed to be a part hereof from the date of filing:

1. The Company's Annual Report on Form 10-K for the fiscal year ended April 30, 2016, as filed with the SEC on July 14, 2016.
2. The information specifically incorporated by reference into the Annual Report from the Company's Definitive Proxy Statement with respect to the 2016 Annual Meeting of Stockholders held on October 13, 2016, as filed with the SEC on August 26, 2016.
3. The Company's Quarterly Report on Form 10-Q for the quarterly periods ended July 31, 2016 and October 31, 2016, as filed with the SEC on September 8, 2016, and December 12, 2016, respectively.
4. The Company's Current Reports on Form 8-K as filed with the SEC on June 2, 2016, June 3, 2016, July 14, 2016, September 6, 2016, September 8, 2016, October 11, 2016, October 12, 2016, October 13, 2016, December 6, 2016, and December 12, 2016.
5. The description of the Company's Common Stock, \$0.001 par value (the "Common Stock"), is contained in the Company's Registration Statements on Form 8-A and Form 8-B (Registration of Successor Issuers) including any amendments or reports filed for the purpose of updating such information.

In addition, all documents subsequently filed by the Company pursuant to Section 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the "Act"), after the date of this Registration Statement and prior to the filing of a post-effective amendment that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents. Any statement contained in a document incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document that is incorporated by reference herein modifies or supersedes such earlier statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

Nothing in this registration statement shall be deemed to incorporate information furnished but not filed with the SEC pursuant to Item 2.02 or Item 7.01 of Form 8-K.

#### Item 5. Interests of Named Experts and Counsel.

Mark R. Ziebell will issue an opinion regarding the validity of the Registrant's common stock offered hereby. Mr. Ziebell is the Registrant's Vice President, General Counsel and Corporate Secretary. Mr. Ziebell does not currently own any shares of the Registrant's outstanding common stock and is eligible to participate in the ESPP.

#### Item 8. Exhibits.

<u>Exhibit Number</u>	<u>Exhibit Description</u>
4.16	2010 Employee Stock Purchase Plan (Incorporated by reference to Exhibit B to Registrant's Definitive Proxy Statement filed with the SEC on August 27, 2010).
4.27	Amendment to the 2010 Employee Stock Purchase Plan (Incorporated by reference to Exhibit B to Registrant's Definitive Proxy Statement filed with the SEC on August 26, 2016)
5.1	Opinion of Counsel
23.1	Consent of Independent Registered Public Accounting Firm
23.2	Consent of Counsel (included in Exhibit 5.1)
24.1	Power of Attorney (included in this Registration Statement under "Signatures")

## SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Tustin, State of California, on December 12, 2016.

PEREGRINE PHARMACEUTICALS, INC.

By: /s/ Steven W. King

Steven W. King,  
President and Chief Executive Officer

## POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints, Steven W. King and Paul J. Lytle, and each of them, as his attorney-in-fact, each with full power of substitution, for him in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and any and all Registration Statements filed pursuant to Rule 462 under the Securities Act of 1933, as amended, in connection with or related to the Offering contemplated by this Registration Statement and its amendments, if any, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorney to any and all amendments to said Registration Statement.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

<u>SIGNATURE</u>	<u>TITLE</u>	<u>DATE</u>
<u>/s/ Steven W. King</u> Steven W. King	President and Chief Executive Officer (Principal Executive Officer), and Director	December 12, 2016
<u>/s/ Paul J. Lytle</u> Paul J. Lytle	Chief Financial Officer (Principal Financial and Principal Accounting Officer)	December 12, 2016
<u>/s/ Carlton M. Johnson</u> Carlton M. Johnson	Director	December 12, 2016
<u>/s/ David H. Pohl</u> David H. Pohl	Director	December 12, 2016
<u>/s/ Eric S. Swartz</u> Eric S. Swartz	Director	December 12, 2016

## [PEREGRINE PHARMACEUTICALS, INC. LETTERHEAD]

December 12, 2016

The Board of Directors  
Peregrine Pharmaceuticals, Inc.  
14282 Franklin Avenue  
Tustin, California 92780

Peregrine Pharmaceuticals, Inc. Registration Statement on Form S-8 (the "Registration Statement")

Gentlemen:

As General Counsel and Corporate Secretary of Peregrine Pharmaceuticals, Inc., a Delaware corporation (the "Company"), I have participated in the preparation and filing by the Company of a Registration Statement on Form S-8 (the "Registration Statement") for the registration under the Securities Act of 1933, as amended (the "Securities Act"), of 10,000,000 shares of the Company's Common Stock, par value \$0.001 per share (the "Shares"), issuable by the Company pursuant to its 2010 Employee Stock Purchase Plan, as amended (the "ESPP"). This opinion is delivered in accordance with the requirements of Item 601(b)(5) of Regulation S-K promulgated under the Securities Act.

In connection with this opinion, I have examined the Registration Statement, the Company's Certificate of Incorporation as in effect on the date hereof, the Company's bylaws as in effect on the date hereof, the ESPP and certain corporate proceedings of the Company as reflected in the minutes of meetings of the Board of Directors of the Company. In such examination, I have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of all documents submitted to me as originals and the conformity to the originals or certified copies of all documents submitted to me as copies thereof. In addition, I have made such other examinations of law and fact as I have deemed necessary or appropriate for the purposes of this opinion.

Based on the foregoing, I am of the opinion that the issuance and sale of the Shares have been duly authorized and, when issued and paid for in accordance with the terms of the ESPP, will be validly issued, fully paid and nonassessable.

I am admitted to practice law in the State of California and my opinion is limited to federal law and the corporate laws of the State of California and the State of Delaware that affect such opinion.

I hereby consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, I do not thereby admit that I am in the category of persons whose consent is required under Section 7 of the Securities Act or the Rules and Regulations of the Securities and Exchange Commission.

Very truly yours,

/s/ Mark R. Ziebell

Mark R. Ziebell  
General Counsel

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-8) to be filed on or about December 12, 2016 pertaining to the 2010 Employee Stock Purchase Plan of Peregrine Pharmaceuticals, Inc. of our reports dated July 14, 2016, with respect to the consolidated financial statements and schedule of Peregrine Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of Peregrine Pharmaceuticals, Inc., included in its Annual Report (Form 10-K) for the year ended April 30, 2016, filed with the Securities and Exchange Commission.

**/s/ Ernst & Young LLP**

Irvine, California  
December 12, 2016